Uflacker Alice, Doraiswamy P Murali
Dr. Uflacker and Dr. Doraiswamy are with the Department of Psychiatry, Duke University, and the Duke Institute for Brain Sciences, Durham, North Carolina (e-mail:
Focus (Am Psychiatr Publ). 2017 Jan;15(1):13-17. doi: 10.1176/appi.focus.20160029. Epub 2017 Jan 11.
Alzheimer's disease is a major public health concern, affecting an estimated 40 million people worldwide. Over the past few years, several new diagnostic tests and new diagnostic nomenclatures have emerged, and more than 70 disease-modifying agents are in clinical trials. Naturalistic studies that include biomarkers-such as genomics, metabolomics, and imaging-have yielded additional insights into disease mechanisms and timelines of preclinical disease onset. This article reviews recent developments in epidemiology, diagnostic criteria, and diagnostic tests; provides updates on symptomatic therapies, ongoing prevention trials, and neuropsychiatric symptom treatment options; and ends with a discussion on prospects for a cure.
阿尔茨海默病是一个重大的公共卫生问题，全球约有4000万人受其影响。在过去几年中，出现了几种新的诊断测试和新的诊断术语，70多种疾病修饰药物正处于临床试验阶段。包括基因组学、代谢组学和成像等生物标志物的自然主义研究，对疾病机制和临床前疾病发作的时间线有了更多的了解。本文综述了流行病学、诊断标准和诊断测试方面的最新进展；提供了症状性治疗、正在进行的预防试验和神经精神症状治疗选择的最新情况；并以对治愈前景的讨论作为结尾。
